Isabi

Executive Summary

Isabi is a San Francisco-based biotechnology company founded in 2018 that aims to transform oncology diagnostics through its comprehensive whole-genome and transcriptome sequencing (WGTS) test. Unlike traditional panel-based tests that cover only a subset of mutations, Isabi's approach analyzes 100% of a tumor's DNA and RNA, enabling the detection of all relevant cancer-associated alterations. This holistic view has the potential to improve diagnostic accuracy and guide more personalized treatment decisions. The company's technology addresses a critical unmet need in precision oncology, where comprehensive genomic profiling is increasingly recognized as essential for optimal patient management. Isabi's platform could compete with established players by offering a more complete and cost-effective solution, though the company is still in early stages and has not publicly disclosed funding or clinical validation data. The market opportunity is substantial as the demand for comprehensive genomic testing grows with the expansion of targeted therapies and immunotherapies. Isabi's success will depend on its ability to demonstrate clinical utility, achieve regulatory clearance, and secure partnerships for commercial distribution. The company's progress in the highly competitive diagnostics landscape will be closely watched by investors and clinicians seeking alternatives to current fragmented testing approaches.

Upcoming Catalysts (preview)

• TBDFDA clearance of WGTS test for solid tumor profiling40% success
• Q3 2026Partnership with a major academic cancer center for clinical validation70% success
• Q4 2026Series A funding round to scale operations and clinical studies65% success